VILLOCENTESI O AMNIOCENTESI? Vantaggi e svantaggi da una esperienza di 115 000 analisi cromosomiche prenatali



Similar documents
MASSIVELY PARALLEL SEQUENCING OF MATE RNAL PLASMA DNA IN 113 CASES OF FETAL NUCHAL CYSTIC HYGROMA

Chromosomes, Karyotyping, and Abnormalities (Learning Objectives) Learn the components and parts of a metaphase chromosome.

LEUKODYSTROPHY GENETICS AND REPRODUCTIVE OPTIONS FOR AFFECTED FAMILIES. Leila Jamal, ScM Kennedy Krieger Institute, Baltimore MD

RECURRENT PREGNANCY LOSS DR.RAJALAKSHMI SRINIVASAN SPECIALIST GYNECOLOGIST ZULEKHA HOSPITAL DUBAI

Chromosomes, Mapping, and the Meiosis Inheritance Connection

Non-Invasive Prenatal Testing (NIPT) Factsheet

your questions answered the reassurance of knowing A guide for parents-to-be on noninvasive prenatal testing.

A test your patients can trust.

The correct answer is c A. Answer a is incorrect. The white-eye gene must be recessive since heterozygous females have red eyes.

Cytogenetic and Molecular Diagnosis in Gestational Disorders

fi АУ : fi apple Ав Ав АУ . apple, АУ fiав Ав. АК applefi АУ, АУАв Ав fi АУ apple fi Ав. А applefi АУ АУ АУ АсА» Ас Ам, длappleapple Ас...

Complimentary and personal copy for

Genetics and Pregnancy Loss

Trisomy 13 (also called Patau s syndrome or T13)

A test your patients can trust. A company you know and trust.

Genetics in Family Medicine: The Australian Handbook for General Practitioners Testing and pregnancy

REI Pearls: Pitfalls of Genetic Testing in Miscarriage

4.2 Meiosis. Meiosis is a reduction division. Assessment statements. The process of meiosis

1. PRENATAL DIAGNOSIS OF CHROMOSOMAL DISORDERS - molecular aspects

Executive summary. Current prenatal screening

Non-invasive prenatal detection of chromosome aneuploidies using next generation sequencing: First steps towards clinical application

... INTERNATIONAL SYMPOSIUM ON:

First Trimester Screening for Down Syndrome

Basic Human Genetics: Reproductive Health and Chromosome Abnormalities

Chapter 9 Diagnostic testing for trisomy 18

The genetic screening of preimplantation embryos by comparative genomic hybridisation

Fluorescence in situ hybridisation (FISH)

In most developed countries, prenatal screening

National Down Syndrome Society

Gutenberg Center in MALAGA

Each person normally has 23 pairs of chromosomes, or 46 in all. We inherit one chromosome per pair from our mother and one from our father.

cfdna in maternal plasma obtained from a population undergoing routine screening at weeks gestation.

Outline PARTE I. PARTE I Assemblaggio rivelatori a GEM Tripla presso la G&A

Invasive Prenatal (Fetal) Diagnostic Testing

The New Luxury World: l identità digitale nel lusso fa la differenza

CHROMOSOMES Dr. Fern Tsien, Dept. of Genetics, LSUHSC, NO, LA

The New Luxury World: l identità digitale nel lusso fa la differenza

Prenatal screening and diagnostic tests

Prenatal Testing Special tests for your baby during pregnancy

Versione: 2.1. Interoperabilità del Sistema di Accettazione di SPT

Scrivere un articolo Statistica. Valter Torri Dip. Oncologia

How To Test An Electronic Board With A Flying Probe Tester

Obstetrical Ultrasound and Prenatal Diagnostic Center

Inclusion of Early Fetal Deaths in a Birth Defects Surveillance System

Available online at Taiwanese Journal of Obstetrics & Gynecology 51 (2012) 77e82. Short Communication. Accepted 25 October 2011

Progetto Ombra Milano propone un nuovo progetto dal design tutto italiano. Una SCALA di prestigio accessibile a tutti.

E U R O P E A N C U R R I C U L U M V I T A E F O R M A T PERSONAL INFORMATION

Carrier detection tests and prenatal diagnosis

CHROMOSOMES AND INHERITANCE

Examination of trisomy 13, 18 and 21 foetal tissues at different gestational ages using FISH

The first 3,000 Non-Invasive Prenatal Tests (NIPT) with the Harmony test in Belgium and the Netherlands

Prenatal screening and diagnosis of chromosomal and genetic abnormalities in the fetus in pregnancy

Noninvasive Prenatal Screening for Fetal Aneuploidies and Microdeletions Using Cell-Free Fetal DNA

Triploidy. rarechromo.org

scale per l arredamento d interni stairs for interior design

Trisomies 13 and 18. -Maternal age. (Patau and Edward s syndrome)

Your 2 nd best friend

UNIT 13 (OPTION) Genetic Abnormalities

***Next Generation sequencing testing options available effective April 18 th, 2016***

Lezione Xl-Xll giovedì 27-X-2011

Noninvasive Prenatal Testing for Fetal Aneuploidies Using Cell- Free Fetal DNA

Primiano Tucci Università di Bologna

Response Definition, Evaluation and Monitoring. Michele Baccarani

The following chapter is called "Preimplantation Genetic Diagnosis (PGD)".

Le dépistage prénatal First-trimester syndrome de Down. grossesse aneuploidies SUMMARY AGENCE D ÉVALUATION DES TECHNOLOGIES

Optimal Detection of Fetal Chromosomal Abnormalities by Massively Parallel DNA Sequencing of Cell-Free Fetal DNA from Maternal Blood

***Next Generation sequencing testing options available effective April 18 th, 2016***

The costs of having a baby. Private system

Current Status in Non-Invasive Prenatal Detection of Down Syndrome, Trisomy 18, and Trisomy 13 Using Cell-Free DNA in Maternal Plasma

First-trimester prenatal screening for Down syndrome and other aneuploidies AGENCE D ÉVALUATION DES TECHNOLOGIES ET DES MODES D INTERVENTION EN SANTÉ

The California Prenatal Screening Program

APC-Pro sa Computer Service

Birth defects. Report by the Secretariat

«Software Open Source come fattore abilitante dei Progetti per le Smart Cities»

Universal Fetal Cardiac Ultrasound At the Heart of Newborn Well-being

Fuld Skolerapport for Hunderupskolen, i Odense kommune, for skoleår 2013/2014 for klassetrin(ene) 7. med reference Tilsvarende klassetrin i kommunen

Fuld Skolerapport for Søhusskolen, i Odense kommune, for skoleår 2013/2014 for klassetrin(ene) 9. med reference Tilsvarende klassetrin i kommunen

Trisomy 13 detection in the first trimester of pregnancy using a chromosome-selective cell-free DNA analysis method

tel fax

Industrial Control Systems Security. Denny Gregianin_Sales Area Manager

The National Down Syndrome Cytogenetic Register for England and Wales: 2008/9 Annual Report

What Is Genetic Counseling? Helping individuals and families understand how genetics affects their health and lives

Sonographic screening for trisomy 13 at 11 to 13 D6 weeks of gestation

PROFESSIONAL GUIDELINES FOR CLINICAL CYTOGENETICS AND CLINICAL MOLECULAR GENETICS

Human Chromosomes lab 5

Statistics Jobs. La mia esperienza nell industria farmaceutica Silvia Barbi, Statistician at Novartis Vaccines Bologna, 9 Maggio 2014

Cloud Services: cosa sono e quali vantaggi portano alle aziende manifatturiere

*Please consult the online schedule for this course for the definitive date and time for this lecture.

Nuovi Scenari in Oncologia. G. Zoppoli X-Files in Nutrizione Clinica e Artificiale, 08/06/2012

Maternal serum free b-hcg and PAPP-A in fetal sex chromosome defects in the rst trimester

fiat seicento manual free : The User's Guide

MANY CERTIFICATES WHAT S THE WORTH?

1.- L a m e j o r o p c ió n e s c l o na r e l d i s co ( s e e x p li c a r á d es p u é s ).

Screening for chromosomal abnormalities at weeks: the role of ductus venosus blood flow

Intelligent Motorola Portable Radio Energy System

New Prenatal Tests for Down Syndrome: Brian G. Skotko, MD, MPP Co-Director, Down Syndrome Program Massachusetts General Hospital

ITALIAN NATIONAL BLOOD CENTRE REGULATION OF CORD BLOOD BANKING: GLOBAL IMPLICATIONS

Down s Syndrome: Ultrasound Screening

DIAGNOSING CHILDHOOD MUSCULAR DYSTROPHIES

Clinical Studies Abstract Booklet

Transcription:

VILLOCENTESI O AMNIOCENTESI? Vantaggi e svantaggi da una esperienza di 115 000 analisi cromosomiche prenatali Prof. Giuseppe SIMONI TOMA, Advanced Biomedical Assays, S.p.A. Controversie e nuove tecnologie nella diagnosi prenatale del primo trimestre: dal laboratorio alle procedure strumentali Bologna, 5 Aprile 2008

1994- January 15th 2008: 115 576 AF AND CVS FREQUENCIES OF UNBALANCED FETAL KARYOTYPES AT AMNIOCENTESIS AND CVS AF N CASES UNBALANCED ABNORMALITIES* % INDICATION Maternal age 70,860 976 1.38% Previous child/fetus with chr abnorm. 742 7 0.94% Balanced chr abnorm. In parents 252 16 6.35% Increased risk at screening test 8,042 195 2.42% Other 4,951 418 8.44% TOTAL 84,847 1612 (1.9%) CVS N CASES UNBALANCED ABNORMALITIES* % INDICATION Maternal age 25997 582 2.24% Previous child/fetus with chr abnorm. 972 20 2.06% Balanced chr abnorm. In parents 209 21 10.05% Increased risk at screening test 445 27 6.07% Other 3106 660 21.25% TOTAL 30729 1310 (4.25%) *UN B A L.A B N OR M. T R IS 21 T R IS 18 T R IS 13 SEX C H R.A N EUP L. M OSA IC S SUP ER N.M A R KER S D E N OVO R EA R R. D EL/ D UP OT H ER

TYPES OF UNBALANCED ABNORMALITIES FOUND AT AMNIOCENTESIS N CASES TRIS 21 697 TRIS 18 174 TRIS 13 72 SEX CHR.ANEUPL. 218 45,X 53 OT H ER SEX C H R A B N 165 MOSAICS 219 SUPERN.MARKERS 47 TRIPLOIDS 27 OTHERS 158 TOTAL 1612 REL. PROPORTION (%) 43.24% 10.79% 4.47% 13.52% 13.59% 2.92% 1.67% 9.80% 3.29% 10.24% FREQUENCIES OF UNBALANCED FETAL KARYOTYPES AT AMNIOCENTESIS ACCORDING TO MATERNAL AGE N OF CASES N OF UNBALANCED ABNORMALITIES % AGE 35 years 48446 801 1.65% < 35 years 22414 175 0.78%

FREQUENCIES OF THE DIFFERENT TYPES OF UNBALANCED FETAL KARYOTYPES AT AMNIOCENTESIS ACCORDING TO MATERNAL AGE TRIS 21 TRIS 18 TRIS 13 SEX CHR.ANEUPL. 45,X OT H ER SEX C H R MOSAICS SUPERN.MARKERS TRIPLOIDS OTHERS SUBTOTAL TOTAL < 35Y N CASE (%) 35Y N CASE (%) 51 (29,1) 398 (49,7) 5 (2,9) 73 (9,1) 5 (2,9) 27 (3,4) 40 (22,9) 109 (13,6) 32 (18,3) 106 (13,2) 5 (2,9) 25 (3,1) 0 7 (4,0) 33 (18,9) 37 (21,1) 60 (7,5) 175 (17.9) 801 (82.1) 976 3 (0,4) 8 (1,0) 101 (12,6)

TYPES OF UNBALANCED ABNORMALITIES FOUND AT CVS N CASES TRIS 21 623 TRIS 18 230 TRIS 13 84 SEX CHR.ANEUPL. 176 45,X 102 OT H ER SEX C H R A B N 74 MOSAICS confirmed at AF 88 SUPERN.MARKERS 16 TRIPLOIDS 40 OTHERS 53 TOTAL 1310 REL. PROPORTION (%) 47.56% 17.56% 6.41% 13.44% 6.72% 1.22% 3.05% 4.05% 7.79% 5.65% FREQUENCIES OF UNBALANCED FETAL KARYOTYPES AT CHORIONIC VILLI SAMPLING ACCORDING TO MATERNAL AGE N OF CASES N OF UNBALANCED ABNORMALITIES % AGE 35 years 20,596 513 2.49% < 35 years 5,401 69 1.28%

FREQUENCIES OF THE DIFFERENT TYPES OF UNBALANCED FETAL KARYOTYPES AT CVS ACCORDING TO MATERNAL AGE TRIS 21 TRIS 18 TRIS 13 SEX CHR.ANEUPL. 45,X OT H ER SEX C H R A B N MOSAICS SUPERN.MARKERS TRIPLOIDS OTHERS SUBTOTAL TOTAL < 35Y N CASE (%) 35Y N CASE (%) 20 (29,0) 276 (53,8) 5 (7,2) 69 (13,5) 5 (7,2) 24 (4,7) 13 (18,8) 64 (12,5) 8 (11,6) 16 (23,2) 39 (7,6) 1 (1,4) 12 (2,3) 2 (2,9) 11 (2,1) 7 (10,1) 20 (3,9) 69 (11.9) 5 (7,2) 582 513 (88.1) 9 (1,8) 55 (10,7)

SUMMARY OF PRENATAL DIAGNOSIS OF MOSAICISM AT AMNIOCENTESES TYPE OF MOSAICISM Autosomes Sex chromosome Marker chromosome TOTAL N CASES 63 117 39 219 % on total cases 219/84847=0,26%* *Frequencies of True Fetal Mosaicisms at CVS: 10,53% X 2.05% /100= 0.23%

VANTAGGI DELL ANALISI CITOGENETICA SUI VILLI CORIALI MARGINI DI TEMPO SUFFICIENTI PER INDAGINI SUPPLEMENTARI (FISH, ANALISI MOLECOLARI, MLPA ) IDENTIFICAZIONE DI MOSAICISMO SU VILLI CORIALI CONFERMA DEL MOSAICO NEGLI AMNIOCITI (TFM) ESCLUSIONE DI UPD FETALE NEI CASI DI CPM ASSOCIAZIONE DEL RITARDO DI CRESCITA FETALE IDIOPATICO CON CPM

Confined placental mosaicisms Kalousek D., 1984

TIPO I TIPO II TIPO III

MOSAICISM IN CHORIONIC VILLI CONFIRMATORY AMNIOCENTESIS MOSAICISM IN AMNIOCYTES CONFIRMATORY FETAL BLOOD SAMPLING

RISULTATI Frequenze dei differenti tipi di mosaico 24237 mosaicismo CV: 498 (2,05%) 380 AF Table 1: Incidences of the different types of mosaicisms (CPM and TFM) found after chrionic villous and amniocytes karyotyping TYPE NATURE TROPHOBLAST MESENCHYME (direct) (culture) AMNIOCYTES RELATIVE FREQUENCIES I CPM Abnormal Normal Normal 36,58% (139/380) II CPM Normal Abnormal Normal 44,7% (170/380) III CPM Abnormal Abnormal Normal 8,1% (31/380) IV TFM Abnormal Normal Abnormal 1,58% (6/380) V TFM Normal Abnormal Abnormal 4.7% (18/380) VI TFM Abnormal Abnormal Abnormal 4,2% (16/380) *Summary of prenatal diagnosis of Mosaicisms at amniocentesis: 219/84847= 0.26% 10.53%* (40/380) (40/380) = 0.23% CVS = 0.23% CVS SAMPLES SAMPLES

RISULTATI Probabilità di conferma nel feto Table 2: Probabilities of confirmation on amniocytes of Mosaic or Non Mosaic abnormal cell line considering the different combinations of the affected placental tissues TROPHOBLAST MESENCHYME (direct) (culture) CONFIRMATION A N 4,14% (6/145) MA N Type IV/Type I+IV=3/112+3= 2,6% NMA N 3/27+3= 10% N A 9,6% (18/188) N MA Type V/Type II+V= 6/150+6= 3,8% N NMA 12/20+12= 37,5% A A 34% (16/47) MA MA Type VI/Type III+VI= 9/19+9= 28,5% NMA MA 3/9+3= 25% MA NMA 4/0+4= 100% NMA* NMA* 0/3+0= 0% A=Abnormal; N=Normal; MA=Mosaic Abn; NMA=Non Mosaic Abn;*exhotic chr

203 TOTAL CASES OF WHICH 51 INVOLVED AN IMPRINTED CHROMOSOME

VANTAGGI DELL ANALISI CITOGENETICA SU AMNIOCITI CELLULE DERIVATE DA DIVERSI TESSUTI E PARTI FETALE MIGLIORE RISOLUZIONE DEL BANDEGGIO CROMOSOMICO

REPORTED DETECTION RATES (d.r( d.r.).)

REPORTED DETECTION RATES Detection Rates SURUSS (U.K.) (n=47'507) FASTER (U.S.A.) (n=38'033) I TRIMESTER (9-13wg) MESUREMENTS (+MAT. AGE) TRIS 21* TRIS 21* TRIS 18 & OTHER Combined-1 NT+f-β-hCG 65% / / Combined-2 Combined-1+PAPP-A 83% 85% 78% Combined-3 Combined-2+AFP 84% / / Combined-4 Combined-3+uE3 86% / / *False Positive Rate: 5% False Positive Rate: 6% Detection Rates SURUSS (U.K.) (n=47'507) FASTER (U.S.A.) (n=36'171) II TRIMESTER (14-22wg) MESUREMENTS (+MAT. AGE) TRIS 21* TRIS 21* TRIS 18 & OTHER DOUBLE AFP+f-β-hCG 71% / / TRIPLE DOUBLE+uE3 77% 70% / QUADRUPLE TRIPLE+inhA 83% 81% 69% *False Positive Rate: 5% False Positive Rate: 8,9% Detection Rates SURUSS (U.K.) (n=47'507) FASTER (U.S.A.) (n=36'171) I+II TRIMESTER MESUREMENTS (+MAT. AGE) TRIS 21* TRIS 21* TRIS 18 & OTHER Integrated (NT+PAPP-A) + QUADRUPLE 93% 86% / *False Positive Rate: 5%

RELATIVE INCIDENCE OF +21,+18,+13,X0,TRIPLOIDS ON THE TOTAL FETAL CHROMOSOMOPATHY IN OUR SURVEY CV (582 cases with a significant chromosomopathy: Chr. Abnormality N Cases Relative % XXX and XYY excluded) <35 (69 abn. cases) 35 (513 abn. cases) TRIS 21 20 29% TRIS 18 5 7.2% TRIS 13 5 7.2% X0 5 7.2% TRIPLOIDY 2 2.9% 37/69 53.6% TRIS 21 276 53.8% TRIS 18 69 13.5% TRIS 13 24 4.7% X0 9 1.8% TRIPLOIDY 11 2.1% 389/513 75.8% AF (976 cases with a significant chromosomopathy: XXX and XYY excluded) <35 (175 abn. cases) 35 (801 abn. cases) Chr. Abnormality N Cases Relative % TRIS 21 51 29.1% TRIS 18 5 2.9% TRIS 13 5 2.9% X0 7 4.0% TRIPLOIDY 0-68/175 38.9% TRIS 21 398 49.7% TRIS 18 73 9.1% TRIS 13 27 3.4% X0 8 1.0% TRIPLOIDY 3 0.4% 509/801 63.5%

PERCENTAGES OF CHROMOSOMAL ABNORMALITIES ACTUALLY DETECTED BY PRENATAL SCREENING ON THE TOTAL FETAL CHROMOSOMOPATY (1) 1 TRIMESTER TRISOMY 21 +18,+13,X0,TRIPLOIDS 1 TRIMESTER age OBSERVED % a d.r. b DETECTABLE % a % c OBSERVED % a d.r. b DETECTABLE % a % c COMBINED-2 <35 29.0% 35 53.8% 85% 24.6% -4.4% 45.7% -8.1% 24.6% (17/69) 22.0% (113/513) 78% 19.2% -5.5% 17.2% -4.8% 1 TRIMESTER age Σ% OBSERVED Σ% DETECTABLE % d COMBINED-2 <35 35 53.6% 75.8% 43.8% 62.9% -9.80% -12.90% a ON TOTAL FETAL CHROMOSOMOPATHY b Best Reported Detection Rate c partial (DETECTABLE%-OBSERVED%) d total (DETECTABLE%-OBSERVED%)

PERCENTAGES OF CHROMOSOMAL ABNORMALITIES ACTUALLY DETECTED BY PRENATAL SCREENING ON THE TOTAL FETAL CHROMOSOMOPATY (2) 1I TRIMESTER TRISOMY 21 +18,+13,X0,TRIPLOIDS 2 TRIMESTER age OBSERVED % a d.r. b DETECTABLE % a % c OBSERVED % a d.r. b DETECTABLE % a % c DOUBLE TRIPLE QUADRUPLE DOUBLE TRIPLE QUADRUPLE <35 29.1% 35 49.7% 71% 20.7% -8.4% 77% 22.4% -6.7% 83% 24.2% -4.9% 71% 35.3% -14.4% 77% 38.3% -11.4% 83% 41.2% -4.5% 9.7% (17/175) 13.9% (111/801) N.R. / / N.R. / / 69% 6.7% -3.0% N.R. / / N.R. / / 69% 9.6% -4.3% 2 TRIMESTER age Σ% OBSERVED Σ% DETECTABLE % d DOUBLE TRIPLE QUADRUPLE DOUBLE TRIPLE QUADRUPLE <35 35 38.90% 63.50% / / 30.9% / / 50.8% -8.00% -12.70% a ON TOTAL FETAL CHROMOSOMOPATHY b Best Reported Detection Rate c partial (DETECTABLE%-OBSERVED%) d total (DETECTABLE%-OBSERVED%)

IN SUMMARY 100% TOTAL FETAL CHROMOSOMOPATHY 50% 43.8% 56% 62.9% 37% 30.9% 69% 50.8% 49% 0% DETECTABLE NOT DETECTED <35 35 <35 35 1st TRIM-COMBINED 2nd TRIM-QUADRUPLE